Cadrenal
CVKD
Cadrenal (CVKD) news
Recent news
CKD shareholders to sell shares
Recent activity among shareholders of Cadrenal Therapeutics (CKD) has drawn attention as several insiders and investors appear to be reducing their holdings. While no specific insider transactions have been reported for Cadrenal Therapeutics in the provided data, the broader context of shareholder…
AInvest Wire · Oct 7, 2026Cadrenal Therapeutics - Phase 3 trial to assess bleeding as major safety endpoint using ISTH criteria
AInvest Wire · Aug 31, 2026Cadrenal Therapeutics - FDA agrees to placebo control with standard anticoagulation in CAD-1005 phase 3 trial
AInvest Wire · Aug 31, 2026Cadrenal Therapeutics - Co and FDA align on phase 3 study protocol for CAD-1005
AInvest Wire · Aug 31, 2026Cadrenal Therapeutics announces positive outcome from FDA type D meeting for phase 3 registration study of cad-1005 in heparin-induced thrombocytopenia
AInvest Wire · Aug 31, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.